LUSTRAL

This brand name is authorized in Ireland, Israel, Turkey, UK.

Active ingredients

The drug LUSTRAL contains one active pharmaceutical ingredient (API):

1	Sertraline UNII UTI8907Y6X - SERTRALINE HYDROCHLORIDE
	Sertraline is a potent and specific inhibitor of neuronal serotonin (5-HT) uptake in vitro, which results in the potentiation of the effects of 5-HT in animals. It has only very weak effects on norepinephrine and dopamine neuronal reuptake.
	Read more about Sertraline

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUSTRAL Film-coated tablet	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AB06	Sertraline	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AB Selective serotonin reuptake inhibitors
Discover more medicines within N06AB06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	139273, 139275, 14222, 14223, 143752, 162039, 199683
IE	Health Products Regulatory Authority	31345, 31380, 31399, 31561, 31582, 32343, 32576, 32577
IL	מִשְׂרַד הַבְּרִיאוּת	2979, 4273
TR	İlaç ve Tıbbi Cihaz Kurumu	8699532090041, 8699532090140, 8699532095428, 8699532095473, 8699532096739, 8699532098603, 8699532099693